Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

androgen receptor degrader RO7656594

An orally bioavailable androgen receptor (AR) degrader, with potential antineoplastic activity. Upon oral administration, AR degrader RO7656594 targets, binds to and degrades AR, thereby preventing AR-mediated signaling and inhibiting the proliferation of AR-overexpressing tumor cells. AR, a hormone-regulated transcription factor, plays a key role in tumor cell proliferation in castration-resistant prostate cancer (CRPC).

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	AR degrader RO7656594
Code name:	GDC 2992 GDC-2992 GDC2992 RG 6537 RG-6537 RG6537 RO 7656594 RO-7656594 RO7656594

androgen receptor degrader RO7656594

Search NCI's Drug Dictionary